SG11201407880QA - Treatment of solid tumors using coenzyme q10 - Google Patents

Treatment of solid tumors using coenzyme q10

Info

Publication number
SG11201407880QA
SG11201407880QA SG11201407880QA SG11201407880QA SG11201407880QA SG 11201407880Q A SG11201407880Q A SG 11201407880QA SG 11201407880Q A SG11201407880Q A SG 11201407880QA SG 11201407880Q A SG11201407880Q A SG 11201407880QA SG 11201407880Q A SG11201407880Q A SG 11201407880QA
Authority
SG
Singapore
Prior art keywords
lllll
international
llll
coenzyme
treatment
Prior art date
Application number
SG11201407880QA
Inventor
Niven Rajin Narain
John Patrick Mccook
Paul Y Song
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of SG11201407880QA publication Critical patent/SG11201407880QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/181639 A1 (51) International Patent Classification: A01N 35/00 (2006.01) A61K 9/10 (2006.01) A61K 9/19 (2006.01) (21) International Application Number: PCT/US2013/043785 (22) International Filing Date: 31 May 2013 (31.05.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 61/654,245 1 June 2012 (01.06.2012) US (54) Title: TREATMENT OF SOLID TUMORS USING COENZYME Q10 FIGURE 3 A (71) Applicant: BERG PHARMA LLC [US/US]; 1845 Elm Hill Pike, Nashville, TN 37210 (US). (72) Inventors: NARAIN, Niven, Rajin; 73 Fresh Pond Park­ way, Cambridge, MA 02138 (US). MCCOOK, John, Patrick; 4913 Southern Hills Drive, Frisco, TX 75034 (US). SONG, Paul, Y.; 234 Alta Drive, Santa Monica, CA 90402 (US). MACIAS-PEREZ, Ines; 4549 Raccoon Trail, Hermitage, TN 37076 (US). (74) Agents: HANLEY, Elizabeth, A. et al.; McCarter & Eng­ lish, LLP, 265 Franklin Street, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, [Continued on next page] (57) Abstract: The invention provides methods and composi­ tions for treatment of a subject with solid a tumor comprising ad­ ministration of Coenzyme Q10 (CoQIO), particularly when the subject has failed least at one prior chemotherapeutic regimen. WO 2013/181639 A11 lllll llllllll II llllll III lllll lllll III III III lllll lllll lllll lllll lllll llll llll lllllll llll llll DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201407880QA 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10 SG11201407880QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654245P 2012-06-01 2012-06-01
PCT/US2013/043785 WO2013181639A1 (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Publications (1)

Publication Number Publication Date
SG11201407880QA true SG11201407880QA (en) 2014-12-30

Family

ID=49673946

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407880QA SG11201407880QA (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Country Status (17)

Country Link
US (3) US20140017317A1 (en)
EP (1) EP2854528B8 (en)
JP (3) JP6352905B2 (en)
KR (2) KR20200118233A (en)
CN (1) CN104507308A (en)
AU (2) AU2013267166A1 (en)
BR (1) BR112014029954A2 (en)
CA (2) CA2875150C (en)
EA (1) EA032345B1 (en)
ES (1) ES2761449T3 (en)
HK (1) HK1208995A1 (en)
IL (1) IL236008B (en)
IN (1) IN2014DN10734A (en)
MX (2) MX369768B (en)
NZ (1) NZ702369A (en)
SG (1) SG11201407880QA (en)
WO (1) WO2013181639A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011958A (en) 2009-05-11 2012-02-13 Berg Biosystems Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers.
ES2762451T3 (en) 2011-04-04 2020-05-25 Berg Llc Treatment of tumors of the central nervous system with coenzyme Q10
MX369768B (en) * 2012-06-01 2019-11-21 Berg Llc Treatment of solid tumors using coenzyme q10.
CN113797343A (en) * 2013-04-08 2021-12-17 博格有限责任公司 Treatment of cancer using coenzyme Q10 combination therapy
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
US9996463B2 (en) * 2015-11-10 2018-06-12 International Business Machines Corporation Selection and placement of volumes in a storage system using stripes
US20170189350A1 (en) * 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20170255565A1 (en) * 2016-03-02 2017-09-07 Intel Corporation Method and apparatus for providing a contiguously addressable memory region by remapping an address space
WO2018005412A1 (en) * 2016-06-28 2018-01-04 Tien Yang Der Chemoprotective/chemoactive nanodroplets and methods of use thereof
JP7173992B2 (en) 2017-05-17 2022-11-17 バーグ エルエルシー Use of coenzyme Q10 preparations in the treatment and prevention of epidermolysis bullosa
WO2023099436A1 (en) * 2021-12-01 2023-06-08 Gambro Lundia Ab New dialysis fluid

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
US8932649B2 (en) * 2003-11-14 2015-01-13 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
KR20160106194A (en) * 2004-01-22 2016-09-09 유니버시티 오브 마이애미 Topical co-enzyme q10 formulations and methodns of use
JPWO2008069276A1 (en) * 2006-12-06 2010-03-25 株式会社カネカ Cancer therapeutic agent and carcinogenesis inhibitor
EP2136787B1 (en) 2007-03-22 2019-08-21 Berg LLC Topical formulations having enhanced bioavailability
US7732491B2 (en) * 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
EP4074344A1 (en) 2007-12-04 2022-10-19 Arbutus Biopharma Corporation Targeting lipids
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
MX2011011958A (en) * 2009-05-11 2012-02-13 Berg Biosystems Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers.
ES2664793T3 (en) 2010-03-12 2018-04-23 Berg Llc Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof
CA2839270C (en) 2011-06-17 2018-09-18 Berg Llc Inhalable liposomal pharmaceutical compositions
MX369768B (en) 2012-06-01 2019-11-21 Berg Llc Treatment of solid tumors using coenzyme q10.

Also Published As

Publication number Publication date
MX369768B (en) 2019-11-21
KR20150022932A (en) 2015-03-04
MX2019013776A (en) 2020-01-30
CA3090268A1 (en) 2013-12-05
CN104507308A (en) 2015-04-08
US20170216223A1 (en) 2017-08-03
IL236008A0 (en) 2015-02-01
CA2875150A1 (en) 2013-12-05
AU2017202567B2 (en) 2019-06-13
US20220096399A1 (en) 2022-03-31
EA201492187A1 (en) 2015-05-29
MX2014014492A (en) 2015-05-12
EA032345B1 (en) 2019-05-31
CA2875150C (en) 2020-10-27
EP2854528A1 (en) 2015-04-08
NZ702369A (en) 2016-12-23
KR102163948B1 (en) 2020-10-12
EP2854528B8 (en) 2019-10-23
EP2854528A4 (en) 2016-03-09
JP2015518056A (en) 2015-06-25
AU2013267166A1 (en) 2014-12-18
JP6352905B2 (en) 2018-07-04
US20140017317A1 (en) 2014-01-16
IN2014DN10734A (en) 2015-09-04
JP7225167B2 (en) 2023-02-20
JP2020183440A (en) 2020-11-12
EP2854528B1 (en) 2019-09-18
ES2761449T3 (en) 2020-05-19
WO2013181639A8 (en) 2014-12-31
JP2018168164A (en) 2018-11-01
HK1208995A1 (en) 2016-03-24
KR20200118233A (en) 2020-10-14
BR112014029954A2 (en) 2017-06-27
WO2013181639A1 (en) 2013-12-05
AU2017202567A1 (en) 2017-05-11
IL236008B (en) 2018-08-30

Similar Documents

Publication Publication Date Title
SG11201407880QA (en) Treatment of solid tumors using coenzyme q10
SG11201408261UA (en) Syringe
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201407569PA (en) Interrogatory cell-based assays for identifying drug-induced toxicity markers
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201407537YA (en) Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201407370QA (en) Humanized il-7 rodents
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201408678WA (en) Catalysts and methods for polyester production
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201809527UA (en) Methods of treating circadian rhythm sleep disorders
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201805052YA (en) Therapeutic methods using erythrocytes
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201406987UA (en) Glucokinase activator compositions for the treatment of diabetes
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto